{
  "id": "CD015536.PUB2",
  "draft": "What are the benefits and harms of the drug entecavir for people with chronic (long-term) hepatitis B?\n\nKey messages\n- Due to a lack of good-quality evidence, it is unclear what the benefits and harms of the drug entecavir are for people with long-term hepatitis B. The review could not determine if entecavir affects the risk of death or serious unwanted effects (health problems that might be caused by the treatment) when compared to no treatment or a placebo (a dummy treatment).\n- Given that entecavir is a widely used medicine, better and larger studies are needed to understand its effects on outcomes that are important to patients, such as quality of life, and to get a clearer picture of its potential harms.\n\nWhat is chronic hepatitis B and how is it treated?\nChronic hepatitis B is a long-term liver disease that is a major public health problem worldwide. Entecavir is an antiviral medicine that many clinical guidelines recommend as a first-choice treatment for people with chronic hepatitis B. However, these recommendations have not been based on a thorough review that directly compares the effects of entecavir with no treatment or a placebo (a 'dummy' treatment).\n\nWhat did we want to find out?\nWe wanted to review the evidence from clinical trials to understand the benefits and harms of using entecavir to treat children and adults with chronic hepatitis B, compared to giving them no treatment or a placebo.\n\nHow did we carry out the review?\nWe searched for studies that compared the drug entecavir with no treatment or a placebo (a dummy treatment) in children and adults with chronic hepatitis B. We then combined the results from these studies and rated our confidence in the evidence.\n\nWhat did we find?\nThe review included 22 studies with a total of 2940 people diagnosed with chronic hepatitis B. The studies followed participants for between 5 and 228 weeks. Most studies included only adults, while one included only children. The studies compared oral entecavir against either no treatment or a placebo. Compared with no treatment or a placebo, we do not know if entecavir has an effect on the risk of death because no deaths occurred in the studies. We also do not know if entecavir has an effect on the risk of serious unwanted effects. For every 1000 people, this means entecavir might cause anywhere from 44 fewer to 21 more serious unwanted effects. No studies looked at the effect of entecavir on people's quality of life.\n\nWhat are the limitations of the evidence?\nWe are not confident in the evidence for two main reasons. First, people in the studies may have been aware of which treatment they were getting. Second, the studies reported very few serious unwanted effects, which makes the results less certain.\n\nHow up-to-date is this evidence?\nThe evidence is up to date to July 2024.",
  "metrics": [
    {
      "linguistic_evaluation": {
        "words": {
          "value": 499,
          "rating": "within_limit",
          "direction": null,
          "feedback": null
        },
        "sentences": {
          "value": 26,
          "rating": "info",
          "direction": null,
          "feedback": null
        },
        "words_per_sentence": {
          "value": 19.192307692307693,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "passive_voice": {
          "value": 13,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "active_voice": {
          "value": 34,
          "rating": "P50",
          "direction": "higher_better",
          "feedback": null
        },
        "pronouns": {
          "value": 29,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "nominalization": {
          "value": 20,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "nouns": {
          "value": 131,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "flesch_reading_ease": {
          "value": 57.14879566825962,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "flesch_kincaid_grade": {
          "value": 10.056122244488979,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "automated_readability_index": {
          "value": 9.422506551564666,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "coleman_liau_index": {
          "value": 9.194308617234466,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "gunning_fog_index": {
          "value": 14.410390010790815,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "lix": {
          "value": 47.849622321566216,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "rix": {
          "value": 5.5,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "smog_index": {
          "value": 12.055385138137417,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "dale_chall_readability": {
          "value": 6.742659904424233,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "complex_words_dc": {
          "value": 183,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "complex_words": {
          "value": 84,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "long_words": {
          "value": 143,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        }
      },
      "word_count_status": {
        "word_count": 499,
        "limit": 850,
        "status": "within_limit",
        "message": "Word count: 499 ✓ WITHIN LIMIT (≤850 words)"
      },
      "summary": {
        "P25_count": 8,
        "P50_count": 4,
        "P75_count": 6,
        "P90_count": 0,
        "P10_count": 0,
        "BEYOND_P90_count": 0,
        "BELOW_P10_count": 0,
        "total_evaluated": 18,
        "P25_percentage": 44.44444444444444,
        "P50_percentage": 22.22222222222222,
        "P75_percentage": 33.33333333333333,
        "P90_percentage": 0,
        "P10_percentage": 0,
        "BEYOND_P90_percentage": 0,
        "BELOW_P10_percentage": 0,
        "best_quartile_rate": 77.77777777777779,
        "overall_assessment": "HIGHLY CONFORMS TO TYPICAL PLS PATTERNS"
      }
    }
  ],
  "evaluation": [
    {
      "grade": "NOT_APPROVED",
      "feedback": "This draft is well-structured and meets all critical requirements, including word count and factual accuracy. However, a few key revisions are needed to improve clarity for the reader before it can be approved.\n\nHere are the 2 most important improvements:\n\n1. **Clarify the finding on 'serious unwanted effects' to avoid confusion.**\n    *   **The problem:** The text currently says, 'We also do not know if entecavir has an effect on the risk of serious unwanted effects. For every 1000 people, this means entecavir might cause anywhere from 44 fewer to 21 more...' Stating you 'do not know' and then immediately giving a numerical range can seem contradictory to a reader. The issue is not a complete lack of knowledge, but very low certainty in the evidence.\n    *   **Suggested rewrite:** 'The evidence for serious unwanted effects is very uncertain. The results suggest that for every 000 people, entecavir might lead to anywhere from 44 fewer to 21 more serious unwanted effects, but we have very little confidence in this finding.'\n\n2. **Use the more precise definition for 'serious unwanted effects'.**\n    *   **The problem:** The current definition, '(health problems that might be caused by the treatment)', implies a definite causal link. Adverse events are health problems that happen *during* treatment and may or may not be caused by it.\n    *   **Suggested rewrite:** Please use the more accurate definition from the source material: '(serious health problems that may or may not be caused by the treatment)'.",
      "pls_evaluation_summary": "The linguistic analysis shows the draft highly conforms to typical PLS patterns. All 18 metrics fall within the median or best quartile ranges for readability, sentence structure, and vocabulary. For example, the average sentence length (19.19 words) and Flesch-Kincaid Grade Level (10.06) are in the best quartile, indicating strong structural readability. No metrics show significant deviation, suggesting the text is stylistically sound."
    }
  ]
}